Option Care Health, Inc. Common Stock
OPCH
$23.93
+6.45%
Option Care Health, Inc. is a leading provider of home and alternate-site infusion services, specializing in treatments for complex conditions such as bleeding disorders, neurological disorders, heart failure, and chronic inflammatory disorders within the healthcare sector. The company operates as a dominant player in the specialized infusion services market, distinguished by its national scale and focus on cost-effective, patient-preferred care settings outside of traditional hospitals. The current investor narrative is dominated by a significant stock price decline, raising questions about potential headwinds in reimbursement, competitive pressures, or operational challenges, as the stock has dramatically underperformed the broader market over the past year despite its established position.…
OPCH
Option Care Health, Inc. Common Stock
$23.93
Investment Opinion: Should I buy OPCH Today?
Rating: Hold. The core thesis is that OPCH is a deeply oversold stock with a plausible path to recovery, but the risks of further earnings disappointment and margin pressure are too elevated to justify a Buy rating at this juncture.
The stock trades at a seemingly attractive forward P/E of 10.36x based on consensus EPS of $2.76, which is the primary support for the valuation. Additional supportive data points include a reasonable debt-to-equity ratio of 0.96, a respectable ROE of 15.65%, and low sales multiples (P/S of 0.91x). The recent 8.76% bounce off lows suggests some stabilization, but it has occurred on weak overall momentum, lagging the market significantly over all longer periods.
The thesis would upgrade to a Buy if the company demonstrates clear progress toward the $2.76 EPS target in upcoming quarters, shows margin stabilization or expansion from the current 3.67% net margin, and the stock holds firmly above the $20 support level. It would downgrade to a Sell if EPS estimates begin to be cut, the stock breaks below $18.01, or gross margins show further contraction. Based on the available data, the stock appears fairly valued for the high-risk, high-potential-reward scenario it presents, but is not clearly undervalued given the execution risk.
Sign up to view all
OPCH 12-Month Price Forecast
OPCH is a binary turnaround story centered on earnings delivery. The valuation is not demanding if the company hits its numbers, but the margin profile and recent stock performance inspire little confidence. The base case of a choppy, range-bound recovery is most likely, as the company must prove its recovery thesis over several quarters. The stance would upgrade to bullish on confirmation of the EPS ramp and technical strength above $25. It would turn bearish on a breakdown below $18 or a material cut to forward earnings estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Option Care Health, Inc. Common Stock's 12-month outlook, with a consensus price target around $28.33 and implied upside of +18.4% versus the current price.
Average Target
$28.33
0 analysts
Implied Upside
+18.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$22 - $39
Analyst target range
Consensus analyst sentiment appears cautiously optimistic based on earnings projections, with 7 analysts providing coverage, though specific Buy/Hold/Sell ratings and a consensus price target are not provided in the data. The average EPS estimate for the forward period is $2.76, with a tight range from a low of $2.73 to a high of $2.80, indicating strong agreement on the earnings outlook. The absence of a published price target range prevents calculation of implied upside/downside and analysis of the assumptions behind bullish or bearish scenarios. The limited dataset suggests that while there is analyst coverage generating estimates, the lack of visible price targets and ratings could indicate the stock is a mid-cap name with moderate institutional interest, which may contribute to higher volatility and less efficient price discovery, as evidenced by its significant underperformance relative to the market.
Drowning in data?
Find the real signal!
Bulls vs Bears: OPCH Investment Factors
The evidence presents a classic battleground stock. The bear case is currently more visible, anchored by a catastrophic price decline, thin margins, and high short interest that reflect deep market skepticism. However, the bull case is compelling on a valuation basis, with the stock deeply oversold and priced for a dramatic earnings recovery at a low forward multiple. The single most important tension in the investment debate is whether the company can deliver on the analyst consensus for $2.76 in EPS. If it succeeds, the current price represents a significant undervaluation. If it fails, the already-battered stock faces further downside as its primary valuation support evaporates.
Bullish
- Deeply Oversold Technical Condition: The stock trades at $21.23, near the lower end of its 52-week range of $18.01-$36.80, representing a 42% position within that range. This extreme oversold condition, coupled with a recent 8.76% 1-month gain, suggests the severe downtrend may be exhausting itself and presents a potential value entry point.
- Compelling Forward Valuation: The forward P/E ratio of 10.36x is a significant discount to the trailing P/E of 24.88x, reflecting a reset in expectations. This multiple is based on analyst consensus EPS of $2.76, implying the market is pricing in a dramatic earnings recovery at a very reasonable valuation.
- Strong Analyst Earnings Consensus: Analysts show strong agreement on forward profitability, with a tight EPS estimate range of $2.73 to $2.80 around an average of $2.76. This consensus suggests confidence in the company's ability to execute and deliver substantial earnings growth from the trailing EPS of $0.04.
- Healthy Balance Sheet & Returns: The company maintains a solid financial position with a debt-to-equity ratio of 0.96 and a current ratio of 1.53, indicating balanced leverage and good liquidity. Furthermore, a Return on Equity of 15.65% demonstrates efficient use of shareholder capital.
Bearish
- Severe Price & Momentum Collapse: OPCH has dramatically underperformed, down 32.82% over the past year and 35.61% over six months, lagging the S&P 500 by nearly 60 percentage points. This persistent downtrend, despite a low beta of 0.65, signals deep-seated fundamental concerns beyond general market weakness.
- Extremely Thin Profitability Margins: The company operates with very low margins: a gross margin of 18.06%, an operating margin of 5.98%, and a net margin of 3.67%. These figures indicate significant cost pressures and limited pricing power, making earnings highly sensitive to any operational hiccups or reimbursement changes.
- High Short Interest & Skepticism: A short ratio of 2.49 indicates substantial bearish sentiment and skepticism in the market regarding the company's near-term prospects. This creates a technical overhang and potential for volatile price swings on any news.
- Massive Earnings Growth Priced In: The investment thesis hinges entirely on EPS exploding from $0.04 to $2.76. Any failure to meet these aggressive analyst estimates would likely cause the forward P/E of 10.36x to re-rate higher, leading to further multiple compression and price declines.
OPCH Technical Analysis
The prevailing price trend is a pronounced and sustained downtrend, with the stock down 32.82% over the past year and 35.61% over the last six months. Currently trading at $21.23, the price sits near the lower end of its 52-week range of $18.01 to $36.80, positioning it at approximately 42% of that range, which suggests the stock is deeply oversold and may present a value opportunity, though it also signals persistent negative momentum and fundamental concerns. Recent short-term momentum shows a modest recovery attempt, with the stock up 8.76% over the past month, which contrasts sharply with its 3-month decline of 28.64%, indicating a potential stabilization or oversold bounce after a severe sell-off. This divergence suggests the downtrend may be exhausting itself, but the 1-month gain has occurred on weak relative strength, lagging the S&P 500's 26.44% 1-year gain by nearly 60 percentage points. Key technical levels are clearly defined, with immediate support at the 52-week low of $18.01 and major resistance at the 52-week high of $36.80. A breakdown below $18.01 would signal a continuation of the bearish trend and likely trigger further selling, while a sustained move above the recent high near $22.23 is needed to suggest a reversal. The stock's beta of 0.654 indicates it is about 35% less volatile than the broader market, which is unusual given the magnitude of its decline and suggests its sell-off may be more idiosyncratic than market-driven.
Beta
0.65
0.65x market volatility
Max Drawdown
-46.6%
Largest decline past year
52-Week Range
$18-$37
Price range past year
Annual Return
-20.6%
Cumulative gain past year
| Period | OPCH Return | S&P 500 |
|---|---|---|
| 1m | +12.2% | -1.6% |
| 3m | +17.7% | +1.5% |
| 6m | -29.6% | +5.4% |
| 1y | -20.6% | +14.8% |
| ytd | -25.8% | +7.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OPCH Fundamental Analysis
Revenue trajectory data is not available from the provided quarterly financials, but analyst estimates project full-year revenue of approximately $7.70 billion, indicating the company operates at a significant scale. The lack of recent quarterly revenue and growth rate figures limits the analysis of acceleration or deceleration trends, making it difficult to assess the core growth driver behind the stock's price action. Profitability metrics show the company is profitable but with thin margins; net income margin is 3.67%, gross margin is 18.06%, and operating margin is 5.98%. The trailing P/E ratio of 24.88x, based on the provided EPS of $0.04, implies the market was previously valuing the stock for growth, but the current compression toward a forward P/E of 10.36x suggests expectations have been severely reset. The balance sheet appears reasonably healthy with a debt-to-equity ratio of 0.96, indicating a balanced use of leverage, and a current ratio of 1.53, which suggests adequate short-term liquidity. Return metrics are mixed, with a Return on Equity (ROE) of 15.65% that is respectable, but a Return on Assets (ROA) of 6.19% that is more modest, reflecting the asset-intensive nature of the business; the absence of cash flow statement data prevents an assessment of internal funding capability.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OPCH Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E is 24.88x, while the forward P/E is significantly lower at 10.36x, indicating the market expects a substantial increase in earnings, with analyst consensus EPS estimates jumping from a trailing $0.04 to $2.76. This massive gap implies the market is pricing in a dramatic recovery in profitability, but also reflects skepticism as the stock trades at a deep discount to its trailing earnings multiple. Compared to sector averages, data is not available in the provided inputs, preventing a direct peer comparison of P/E, P/S, or EV/EBITDA multiples to assess premium or discount. The stock's Price-to-Sales (P/S) ratio of 0.91x and EV/Sales of 0.77x appear low, which could suggest a discount if industry averages are higher, but this cannot be confirmed. Historical context for valuation is also unavailable due to missing historical ratios data, so it is impossible to determine if the current P/E of 24.88x or P/S of 0.91x is near the top or bottom of the stock's own historical range, limiting the analysis of whether it represents a value opportunity or reflects deteriorated fundamentals.
PE
24.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability and execution. The company's razor-thin net margin of 3.67% leaves little room for error against rising costs, labor inflation, or drug procurement expenses. The business model is highly sensitive to reimbursement rates from government and private payers; any negative changes could directly compress these already-low margins. Furthermore, the investment thesis is entirely predicated on delivering a massive leap in EPS to $2.76; missing this target would severely damage credibility and valuation.
Market & Competitive Risks are heightened by the stock's technical and sentiment profile. Trading near 52-week lows with a short ratio of 2.49, OPCH faces persistent selling pressure and a lack of bullish conviction. As a healthcare services provider, it operates in a competitive and regulated landscape where larger insurers or pharmacy benefit managers could exert pricing pressure. The stock's low beta of 0.65 suggests its decline is idiosyncratic, meaning a broader market recovery may not lift it, exposing it to continued sector-specific outflows or negative sentiment.
Worst-Case Scenario involves a continuation of the operational headwinds that caused the initial collapse, coupled with a failure to achieve the projected earnings rebound. This could trigger analyst downgrades, intensified short selling, and a loss of investor confidence, driving the stock to retest and break its 52-week low of $18.01. A breakdown below this key support could catalyze a downward spiral toward the $15-$16 range, representing a potential loss of 25-30% from the current price of $21.23. The maximum drawdown of -46.65% over the provided period illustrates the stock's capacity for severe losses.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to achieve the consensus EPS of $2.76 would destroy the primary valuation support (forward P/E of 10.36x). 2) Margin Risk: With a net margin of only 3.67%, even small cost increases or reimbursement cuts could erase profitability. 3) Sentiment & Technical Risk: High short interest (ratio 2.49) and a stock price down 32.8% over the past year create a negative feedback loop that can persist regardless of fundamentals. 4) Sector Risk: As a healthcare services provider, it is exposed to regulatory changes and pricing pressure from payers.
The 12-month forecast is bifurcated, with a 50% probability base case target range of $22-$26, a 30% probability bull case target of $32-$36, and a 20% probability bear case target of $16-$19. The base case, which is most likely, assumes the company makes partial progress toward its $2.76 EPS goal but fails to inspire a full valuation re-rating, leading to a muted recovery. The forecast hinges almost entirely on the company's ability to deliver on projected earnings growth in the coming quarters.
OPCH's valuation is a paradox. The trailing P/E of 24.88x seems high for a company with thin margins, but the forward P/E of 10.36x appears very reasonable, implying the market expects massive earnings growth. The Price-to-Sales ratio of 0.91x also suggests a discount to its revenue base. Overall, the stock is fairly valued relative to the high-risk, high-reward scenario it presents. It is not clearly undervalued because the low multiples are contingent on flawless execution of a dramatic profit expansion that has yet to materialize.
OPCH is a high-risk, high-potential-reward stock that may be suitable for speculative investors comfortable with significant volatility. At a forward P/E of 10.36x, it appears cheap if the company delivers on its $2.76 EPS forecast. However, the 32.8% annual decline, thin 3.67% net margin, and high short interest of 2.49 underscore substantial execution risk. It is not a 'good buy' for most investors, but could represent a tactical opportunity for those who have conducted deep due diligence and believe in the earnings recovery narrative.
OPCH is unsuitable for short-term trading due to its low beta (0.65) and idiosyncratic, news-driven price moves that are difficult to predict. It is best approached as a long-term (2-3 year minimum) speculative investment for investors betting on a full operational turnaround. The thesis requires multiple quarters to play out as the company attempts to hit its earnings targets and rebuild investor trust. The lack of a dividend and high volatility further support a longer holding period to ride out potential swings.
